S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

Resverlogix News Headlines (TSE:RVX)

C$1.31
-0.02 (-1.50 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
C$1.18
Now: C$1.31
C$1.32
50-Day Range
C$1.12
MA: C$1.26
C$1.40
52-Week Range
C$0.35
Now: C$1.31
C$4.94
Volume88,124 shs
Average Volume74,102 shs
Market CapitalizationC$273.99 million
P/E Ratio8.85
Dividend YieldN/A
BetaN/A

Headlines

Resverlogix (TSE RVX) News Headlines

Source:
DateHeadline
Resverlogixs apabetalone nabs accelerated review in U.S.; shares up 15%Resverlogix's apabetalone nabs accelerated review in U.S.; shares up 15%
seekingalpha.com - February 3 at 5:16 PM
Resverlogixs apadetalone nabs accelerated review in U.S.; shares up 15%Resverlogix's apadetalone nabs accelerated review in U.S.; shares up 15%
seekingalpha.com - February 3 at 12:16 PM
Resverlogix Receives US FDA Breakthrough Therapy Designation for ApabetaloneResverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
finance.yahoo.com - February 3 at 12:16 PM
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD - Yahoo FinanceResverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD - Yahoo Finance
finance.yahoo.com - January 13 at 4:51 PM
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVDResverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
finance.yahoo.com - January 13 at 4:51 PM
Resverlogix Appoints Dicky To to its Board of Directors - Yahoo FinanceResverlogix Appoints Dicky To to its Board of Directors - Yahoo Finance
finance.yahoo.com - December 21 at 8:31 AM
Resverlogix Appoints Dicky To to its Board of Directors - GlobeNewswireResverlogix Appoints Dicky To to its Board of Directors - GlobeNewswire
www.globenewswire.com - December 20 at 1:29 PM
Resverlogix Appoints Dicky To to its Board of DirectorsResverlogix Appoints Dicky To to its Board of Directors
feeds.benzinga.com - December 20 at 8:57 AM
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
finance.yahoo.com - December 19 at 1:30 PM
Resverlogix Announces Change to its Board of Directors - StreetInsider.comResverlogix Announces Change to its Board of Directors - StreetInsider.com
www.streetinsider.com - December 12 at 5:54 PM
Resverlogix Announces Change to its Board of Directors - GlobeNewswireResverlogix Announces Change to its Board of Directors - GlobeNewswire
www.globenewswire.com - December 11 at 8:54 AM
Resverlogix Announces Change to its Board of DirectorsResverlogix Announces Change to its Board of Directors
finance.yahoo.com - December 11 at 8:54 AM
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019 - GlobeNewswireReminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019 - GlobeNewswire
www.globenewswire.com - December 5 at 6:05 PM
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
finance.yahoo.com - December 5 at 6:05 PM
Resverlogix to Present at the Clinical Trials on Alzheimers Disease Congress 2019 - GlobeNewswireResverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019 - GlobeNewswire
www.globenewswire.com - December 2 at 9:19 AM
Resverlogix to Present at the Clinical Trials on Alzheimers Disease Congress 2019Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
finance.yahoo.com - December 2 at 9:19 AM
Resverlogix Announces Warrant Exercise Incentive Program Toronto Stock Exchange:RVX - GlobeNewswireResverlogix Announces Warrant Exercise Incentive Program Toronto Stock Exchange:RVX - GlobeNewswire
www.globenewswire.com - November 26 at 12:52 AM
Resverlogix Announces Warrant Exercise Incentive Program - Yahoo FinanceResverlogix Announces Warrant Exercise Incentive Program - Yahoo Finance
finance.yahoo.com - November 25 at 7:51 PM
Resverlogix Announces Warrant Exercise Incentive ProgramResverlogix Announces Warrant Exercise Incentive Program
finance.yahoo.com - November 25 at 7:51 PM
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
finance.yahoo.com - November 12 at 12:54 PM
RVX.TO: Some Clarity on the Path ForwardRVX.TO: Some Clarity on the Path Forward
finance.yahoo.com - November 4 at 1:22 PM
Zenith Announces Voting Results from the 2019 Annual and Special Meeting of ShareholdersZenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders
finance.yahoo.com - October 31 at 11:13 PM
Resverlogix Announces Voting Results from the 2019 Annual Meeting of ShareholdersResverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
finance.yahoo.com - October 31 at 11:13 PM
2 TSX 30 Growth Stocks With Returns That Will Make Your Jaw Drop2 TSX 30 Growth Stocks With Returns That Will Make Your Jaw Drop
www.fool.ca - October 31 at 1:12 PM
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics TrialResverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
finance.yahoo.com - September 30 at 4:49 PM
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of LoanResverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
finance.yahoo.com - September 27 at 4:41 PM
Resverlogix to Host BETonMACE Webcast and Conference CallResverlogix to Host BETonMACE Webcast and Conference Call
www.benzinga.com - September 26 at 7:34 PM
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
finance.yahoo.com - September 23 at 4:18 PM
Resverlogix Provides Update on BETonMACE Phase 3 TrialResverlogix Provides Update on BETonMACE Phase 3 Trial
finance.yahoo.com - September 16 at 10:31 AM
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
finance.yahoo.com - August 14 at 10:08 AM
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
finance.yahoo.com - August 6 at 10:47 AM
Resverlogix Announces Loan Reduction and ExtensionResverlogix Announces Loan Reduction and Extension
finance.yahoo.com - August 2 at 5:56 PM
Resverlogix Announces Publication on Apabetalone in Clinical EpigeneticsResverlogix Announces Publication on Apabetalone in Clinical Epigenetics
finance.yahoo.com - July 15 at 10:33 AM
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety VisitsResverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
finance.yahoo.com - July 8 at 10:17 AM
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with PfizerZenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
finance.yahoo.com - June 27 at 10:32 AM
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics TrialResverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
finance.yahoo.com - June 12 at 1:52 PM
Resverlogix Announces Participation at Leading, International Scientific ConferencesResverlogix Announces Participation at Leading, International Scientific Conferences
finance.yahoo.com - June 10 at 11:18 AM
Resverlogix Announces Closing of $15 Million OfferingResverlogix Announces Closing of $15 Million Offering
finance.yahoo.com - June 7 at 6:55 PM
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
finance.yahoo.com - May 6 at 10:31 AM
Resverlogix Announces 3-Month Loan ExtensionResverlogix Announces 3-Month Loan Extension
finance.yahoo.com - May 2 at 5:17 PM
RVX: 250 Events Reached!RVX: 250 Events Reached!
finance.yahoo.com - April 29 at 4:55 PM
Resverlogix Corp: Resverlogix BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE EventsResverlogix Corp: Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
www.finanznachrichten.de - April 18 at 11:11 AM
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE EventsResverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
finance.yahoo.com - April 18 at 11:11 AM
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimers & Parkinsons DiseasesResverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer's & Parkinson's Diseases
feeds.benzinga.com - April 1 at 11:48 AM
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference ...Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference ...
www.globenewswire.com - April 1 at 11:46 AM
Resverlogix Announces $15.1 Million of Private PlacementsResverlogix Announces $15.1 Million of Private Placements
finance.yahoo.com - April 1 at 11:46 AM
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s DiseasesResverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
finance.yahoo.com - April 1 at 11:46 AM
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of ApabetaloneResverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
finance.yahoo.com - March 27 at 5:20 PM
Resverlogix also advances its Fabry Disease indication data and planningResverlogix also advances its Fabry Disease indication data and planning
www.globenewswire.com - March 18 at 5:30 PM
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University ResearcherResverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
finance.yahoo.com - March 18 at 5:30 PM
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel